The role of intravenous iron in anemia management and transfusion avoidance. (يفتح نافذة جديدة)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Source‎: Transfusion 2008;48(5):988-1000.

مفهرسة‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (يفتح نافذة جديدة)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (يفتح نافذة جديدة)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Source‎: BJU Int 2011;108(10):1582-7.

مفهرسة‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (يفتح نافذة جديدة)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (يفتح نافذة جديدة)

Lepor H, Lipkin M, Slova D.

Source‎: Urology 2010;75(6):1424-8.

مفهرسة‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (يفتح نافذة جديدة)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (يفتح نافذة جديدة)

Nieder AM, Rosenblum N, Lepor H.

Source‎: Urology 2001;57(4):737-41.

مفهرسة‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (يفتح نافذة جديدة)